BeiGene (ONC) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending approval of Tevimbra, in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic NPC.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating
- BeiGene Holds Annual Shareholders Meeting, Key Resolutions Passed
- BeiGene price target raised to $350 from $348 at Guggenheim
- BeiGene’s Strong Market Position and Promising Financial Outlook Drive Buy Rating
- BeiGene Reports Strong Q1 2025 Growth and Profitability